President Donald Trump proposed that Medicare pay for some drugs based on prices in other countries. The administration is launching a demonstration project to base prices for Medicare Part B drugs, those administered in a doctor’s office, on an “international price index.” (New York Times)

Trump’s proposal could hit three pharma companies particularly hard: Amgen, Genentech, and Regeneron. Four Amgen drugs cost significantly more in the U.S. than in Europe. Meanwhile, Genentech and Regeneron’s age-related macular degeneration drugs are some of the costliest Medicare drugs. (STAT)

Amazon is planning to sell consumer health monitors in an exclusive deal with Arcadia Group. The new line, called Amazon Choice, will include products like blood pressure cuffs and glucose monitors. The deal would give Amazon access to patients with chronic disease like diabetes or hypertension and continue its move into the healthcare space. (CNBC)

Third-quarter sales of Merck’s Keytruda jumped 82% over last year. The immunotherapy brought in nearly $1.9 billion in global sales. Non-small cell lung cancer prescriptions of Keytruda account for 65% of its revenue, an area where Merck has an edge over competitor Opdivo. (BioPharma Dive)

Biogen and Eisai’s experimental Alzheimer’s drug showed effectiveness, but investors are skeptical. An analysis looked at the highest dose of the Alzheimer’s drug and showed patients experienced 30% less cognitive decline after 18 months of treatment than those on a placebo. (Reuters)